Q Chip announces new agreement
2nd December 2011
Cardiff, 30th November 2011
Q Chip Ltd, the developer of sustained release drug depots, announces today that it has signed an agreement with a leading international speciality pharmaceutical company to undertake the development of a sustained release depot of an undisclosed therapeutic peptide.
All the costs of preclinical and clinical development will be borne by Q Chip’s partner. In addition, Q Chip will receive substantial success based payments, and will provide the manufactured product after regulatory approval.
Ken Powell, Executive Chairman of Q Chip, said: “This landmark deal is validation of the unique drug encapsulation technology developed at Q Chip. It is our fourth collaboration signed in the last twelve months. Development will take place within our laboratories in Cardiff and at Q Chip BV, our cGMP facility at Geleen, near Maastricht, in the Netherlands.”
Q Chip - www.q-chip.com
Q Chip Ltd is a biopharmaceutical company developing sustained release injectable depot formulations. Q Chip’s proprietary encapsulation technology platform, Q-SpheraTM, represents a paradigm shift in bioencapsulation technology for the production of drug loaded microspheres. Q Chip has developed a suite of manufacturing devices which enable the benign processing of polymer/drug formulations into mono-dispersed microspheres for subcutaneous, intramuscular/ocular administration. These devices are compatible with a wide range of therapies including small molecules, peptides, oligonucleotides, proteins and cells. In addition, microsphere formulation can also be customised to provide sustained release over weeks or months.
Contact:
Q Chip Ltd
Dr Tony Mills, Chief Commercial Officer
Tel: + 44 (0) 29 2048 0180 Email: tony.mills@q-chip.com
M: Communications
Mary Clark
Tel: +44 207920 2361 Email: clark@mcomgroup.com
